Underutilization of preventive strategies in patients receiving NSAIDs

Rheumatology

Volumn 42, Issue SUPPL. 3, 2003, Pages

  Sturkenboom, M C J M ^a   Burke, T A ^c   Dieleman, J P ^a   Tangelder, M J D ^b   Lee, F ^c   Goldstein, J L ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Medical Department   (Netherlands)

^c PFIZER INC   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Drug utilization; Gastrointestinal events; Gastrointestinal risk; NSAIDs; Preventive strategies

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARTHROTEC; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MELOXICAM; MISOPROSTOL; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA BASE; DRUG EFFICACY; DRUG INDICATION; DRUG USE; DRUG UTILIZATION; DYSPEPSIA; ELECTRONIC MEDICAL RECORD; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OSTEOARTHRITIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH PROTECTION; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; ANTACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; DRUG UTILIZATION; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; MISOPROSTOL; NETHERLANDS; PEPTIC ULCER; PROGNOSIS; PYRAZOLES; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 0242609399     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Nonprescription drugs USA 1999, Internal Analgesics Product Category. Little Falls, New Jersey: Kline & Co., 1999.
2. Retail & Provider Perspective, National Prescription Audit, 1999-2000. Plymouth, Pennsylvania: IMS Health, 2000.
3. Infoscan Services, Internal Analgesics Category, Total Food, Drug and Mass Merch, 52 weeks ending July 16, 2000. Plymouth, Pennsylvania: Information Resources, Inc., 2000.
4. Gabriel SE, Wagner JL. Costs and effectiveness of nonsteroidal anti-inflammatory drugs: the importance of reducing side effects. Arthritis Care Res 1997;10:56-63.
5. Chevat C, Pena BM, Al MJ, Rutten FF. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 2001;19(Suppl. 1):17-32.
6. Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Shneidman R. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organisation. Pharmacoeconomics 1997;12:76-88.
7. Moore RA. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology 2002; 41(Suppl. 1):7-15.
8. Sturkenboom MC, Romano F, Simon G et al. The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum 2002;47:132-40.
9. Herings RMC, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001;19:655-65.
10. Rabeneck L, Wristers K, Goldstein JL et al. Reliability, validity, and responsiveness of Severity of Dyspepsia Assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol 2002;97:32-9.
11. Goldstein J, Eisen G, Burke T et al. Dypsepsia tolerability from the patients' perspective: a comparison of celecoxib and diclofenac. Aliment Pharmacol Ther 2002;16:819-27.
12. Fries JF, Williams CA, Bloch DA, Michel BA. Non-steroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91: 213-22.
13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99. [Published erratum appears in N Engl J Med 1999;341:548].
14. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology 2001; 120:594-606.
15. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:2037-46.
16. Schoenfeld P, Kimmey M, Scheiman J, Bjorkman D, Laine L. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications - guidelines for prevention and treatment. Aliment Pharmacol Ther 1999;13:1273-85.
17. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43: 1905-15.
18. Hunt RH, Barkun AN, Baron D et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002;16:231-40.
19. Huisartsengenootschap N. NHG standpoint about prevention of NSAID induced G1 problems and the place of COXIBs. http://nhg.artsennet.nl/index.asp?a=28288&s=1481&p=1.
20. American Pain Society. Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview, IL: American Pain Society, 2002.
21. National Institute for Clinical Excellence. Guidance on the use of cyclooxygenase (COX) II selective inhibitors celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. National Institute for Clinical Excellence. Technology Appraisal Guidance No. 27. Available at http://www.nice.org.uk/pdf/coxiifullguidance.pdf. [Accessed 1 March 2003].
22. van der Lei J, Duisterhout JS, Westerhof HP et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119:1036-41.
23. Vlug AE, van der Lei J, Mosseveld BM et al. Post-marketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38: 339-44.
24. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992;9:330-9.
25. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
26. Smalley W, Stein CM, Arbogast PG et al. Under-utilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-200.
27. van Dijk KN, ter Huurne K, de Vries CS et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002;24:100-3.
28. Langman MJ, Kahler KH, Kong SX et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom [abstract]. Ann Rheum Dis 1999;58(Suppl.):202.
29. Schnitzer TJ, Kong SX, Mavros P, Straus WL, Watson DJ. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 2001;23: 1984-98.
30. Hogan DB, Campbell NR, Crutcher R, Jennett P, MacLeod N. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. CMAJ 1994;151: 315-22.
31. Kephart G, Sketris I, Smith M, Maheu A, Brown M. Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Clin Ther 1995;17:1159-73.
32. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001;52: 185-92.
33. Cohen Y, Freeman NL, Kong SX, Arbel D. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs: analysis of a population cohort in Israel [abstract]. European League Against Rheumatism 2001, Prague, Czech Republic, June 13-16, 2001.
34. Clinard F, Bardou M, Sgro C et al. Non-steroidal antiinflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Clin Pharmacol 2001;57:737-43.
35. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
36. Caputi AP, Kong SX, Mavros P, Ricci E, Russo A. Concomitant use of gastroprotective agents among users of nonsteroidal antiinflammatory drugs in Italy [abstract]. Ann Rheum Dis 2001;60(Suppl. 1):275.
37. Bakowsky V, Hanly J. Complications of nonsteroidal antiinflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center. J Rheumatol 1999;26:1557-63.
38. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.
39. Yeomans N, Wilson I, Langstrom G et al. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001;30:328-34.
40. Griffin MR, Scheiman JM. Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. Am J Med 2001;110:33S-37S.
41. Wolfe MM. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. Int J Clin Pract Suppl 2003;Apr:32-7.
42. Laine L, Bombardier C, Ramey DR et al. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (Vioxx GI Outcomes Research) study [abstract]. European League Against Rheumatism 2001, Prague, Czech Republic, June 13-16, 2001.
43. Langman MJS, Mavros P, Kong SX. Determinants of initiation of COX-2 inhibitors versus NSAIDs and concurrent use of gastroprotective agents in the United Kingdom [abstract]. European League Against Rheumatism 2002, Stockholm, Sweden, June 12-15, 2002.
44. Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. MedGenMed 2001;3:6. accessible at http://www.medscape.com/viewarticle/408199.
45. Rahme E, Marentette MA, Kong SX, Lelorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.